类淀粉沉积症治疗市场规模、份额和成长分析（按类型、最终用途和地区划分）—产业预测（2026-2033 年）

预计到 2024 年，全球类淀粉沉积症治疗市场规模将达到 63.2 亿美元，到 2025 年将达到 68 亿美元，到 2033 年将达到 122.1 亿美元，预测期（2026-2033 年）的复合年增长率为 7.6%。

类淀粉沉积症治疗市场正经历显着扩张，这主要得益于人们对这种罕见疾病的认识不断提高以及诊断能力的增强。淀粉样变性是一种由异常蛋白质沉积引起的罕见疾病，会导致器官功能障碍。推动市场成长的关键因素包括治疗方案的进步，例如化疗、干细胞移植以及创新标靶治疗，如单株抗体和小分子抑制剂，这些疗法在阻止或逆转疾病进展方面展现出巨大潜力。製药公司不断增加的研发投入也促进了市场竞争，推动治疗方案的拓展。然而，挑战依然存在，例如治疗费用的可负担性以及早期诊断对改善患者预后的重要性。持续的研究投入和更有效治疗方法的开发有望维持这一市场成长趋势。

类淀粉沉积症治疗的驱动因素

推动类淀粉沉积症治疗市场发展的主要因素是该疾病发生率的不断上升，其中包括AL型类淀粉沉积症和ATTR型类淀粉沉积症。公众意识的提高和诊断技术的进步使得更多病例得以确诊。诊断病例的激增导致需要有效治疗方案的患者人数增加。随着类淀粉沉积症的认识不断加深，以及需要治疗的患者人数不断增长，预计该市场将显着增长，从而满足患者对创新治疗方法和综合管理方案的迫切需求。

限制类淀粉沉积症治疗市场的因素

由于有效治疗方案有限，类淀粉沉积症治疗市场面临严峻挑战。儘管研发取得了进展，但现有治疗方法仍无法为许多患者带来满意的疗效。现有治疗方法往往不足，凸显了开发更具创新性和高效性的治疗方案的迫切需求。因此，寻求更有效的治疗方法仍然是市场的焦点，患者和医疗服务提供者都希望在应对这种复杂且棘手的疾病时获得更好的疗效。这项限制因素也凸显了该领域持续研发的迫切性。

类淀粉沉积症治疗市场趋势

在标靶治疗的推动下，类淀粉沉积症治疗市场目前正经历显着的进展。该领域的研究和开发日益集中于创新单株抗体和小分子化合物，旨在抑制淀粉样蛋白的生成和沈积，而淀粉样蛋白正是疾病进展的核心。目前正在进行多项临床试验，以探索这些前景广阔的新治疗方法的安全性和有效性，这令人对其改善患者预后的潜力充满信心。这一趋势标誌着医疗策略正朝着更个人化的方向发展，有望提高治疗效果，并更好地管理这种复杂的疾病。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

全球类淀粉沉积症治疗市场规模（按类型划分）、复合年增长率（2026-2033 年）

• 药物治疗
  • 化疗
  • 标靶治疗
  • 抗血管新生疗法
  • 单株抗体
  • 蛋白酶体抑制剂
• 外科手术
  • 骨髓移植/干细胞移植
  • 器官移植

全球类淀粉沉积症治疗市场规模（依最终用途划分）、复合年增长率（2026-2033 年）

• 医院和诊所
• 门诊手术中心
• 居家医疗环境
• 其他的

全球类淀粉沉积症治疗市场规模，复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Alnylam Pharmaceuticals（United States）
• Ionis Pharmaceuticals（United States）
• Intellia Therapeutics（United States）
• Genmab（Denmark）
• Pfizer（United States）
• BridgeBio Pharma（United States）
• Eidos Therapeutics（United States）
• Prothena Corporation（United States）
• Alexion Pharmaceuticals（United States）
• SOM Biotech（Spain）
• Neurimmune（Switzerland）
• Corino Therapeutics（United States）
• Proclara Biosciences（United States）
• Arcturus Therapeutics（United States）
• Dicerna Pharmaceuticals（United States）
• GlaxoSmithKline（United Kingdom）
• Johnson & Johnson（United States）
• Novartis（Switzerland）
• Roche（Switzerland）

结论与建议

Amyloidosis Treatment Market size was valued at USD 6.32 Billion in 2024 and is poised to grow from USD 6.8 Billion in 2025 to USD 12.21 Billion by 2033, growing at a CAGR of 7.6% during the forecast period (2026-2033).

The amyloidosis treatment market is experiencing notable expansion, driven by heightened awareness and improved diagnostic capabilities for this rare disease, where abnormal protein deposits lead to organ dysfunction. Key factors propelling market growth include advancements in therapeutic options, such as chemotherapy, stem cell transplants, and innovative targeted therapies like monoclonal antibodies and small molecule inhibitors that demonstrate potential in halting or reversing disease progression. Increased investment from pharmaceutical companies in research and development is fostering a competitive environment, with a focus on expanding treatment alternatives. However, challenges persist, particularly in terms of treatment affordability and the critical need for early diagnosis to enhance patient outcomes. Continued research efforts and the development of more effective therapies are poised to sustain this market's growth trend.

Top-down and bottom-up approaches were used to estimate and validate the size of the Amyloidosis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Amyloidosis Treatment Market Segments Analysis

Global Amyloidosis Treatment Market is segmented by Type, End-use and region. Based on Type, the market is segmented into Medication and Surgery. Based on End-use, the market is segmented into Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Amyloidosis Treatment Market

A notable factor propelling the amyloidosis treatment market is the increasing incidence of the disease, which encompasses both AL amyloidosis and ATTR amyloidosis. With enhanced awareness and advancements in diagnostic techniques, a higher number of cases are being identified. This surge in diagnosis contributes to a growing patient population requiring effective treatment options. As the understanding of amyloidosis expands and more individuals are recognized as needing care, the market is positioned for significant growth, addressing the essential need for innovative therapies and comprehensive management solutions for those affected by this condition.

Restraints in the Amyloidosis Treatment Market

The amyloidosis treatment market faces significant challenges due to the limited availability of effective therapeutic options. Despite progress in research and drug development, current treatments do not yield satisfactory results for many patients affected by this condition. The existing therapies often fall short in their effectiveness, highlighting a critical need for the development of more innovative and efficient treatment solutions. Consequently, the quest for improved therapies remains a central concern within the market, as patients and healthcare providers seek better outcomes in managing this complex and challenging disease. This limitation underscores the urgency for continued research and advancement in the field.

Market Trends of the Amyloidosis Treatment Market

The amyloidosis treatment market is currently experiencing significant advancements driven by a strong focus on targeted therapies. Research and development in this sector are increasingly centered on innovative monoclonal antibodies and small molecules aimed at inhibiting the production or deposition of amyloid proteins, which are central to disease progression. With numerous clinical trials exploring the safety and efficacy of these promising novel therapies, there is a growing optimism regarding their potential to transform patient outcomes. This trend highlights a shift towards more personalized medicine strategies, enhancing treatment efficacy, and possibly leading to better management of this complex disease.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Amyloidosis Treatment Market Size by Type & CAGR (2026-2033)

• Market Overview
• Medication
  • Chemotherapy
  • Targeted therapy
  • Anti-Angiogenesis Therapy
  • Monoclonal Antibodies
  • Proteasome Inhibitors
• Surgery
  • Bone Marrow Transplantation/Stem Cell Transplantation
  • Organ Transplantation

Global Amyloidosis Treatment Market Size by End-use & CAGR (2026-2033)

• Market Overview
• Hospitals & Clinics
• Ambulatory Surgical Centers
• Home Care Settings
• Others

Global Amyloidosis Treatment Market Size & CAGR (2026-2033)

• North America (Type, End-use)
  • US
  • Canada
• Europe (Type, End-use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, End-use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, End-use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, End-use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Alnylam Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionis Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intellia Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genmab (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BridgeBio Pharma (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eidos Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Prothena Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alexion Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SOM Biotech (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neurimmune (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Corino Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Proclara Biosciences (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arcturus Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dicerna Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations